Theravance Biopharma

901 Gateway Boulevard
South San Francisco, CA 94080

Theravance Biopharma News

FDA accepts Theravance Biopharma sNDA on Vibativ

Friday, Sep 11, 2015 @ 6:10pm by BioPrepWatch Reports

Theravance Biopharma, Inc. said Thursday that the the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for its drug Vibativ ( telavancin) to expand its label to include treatment of Staphylococcus aureus.
Read More »